跳至主要内容
临床试验/NL-OMON53628
NL-OMON53628尚未招募不适用

The diagnostic value of FAPI PET/CT in staging of newly diagnosed PCa - proFAPI

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • - Male, aged >= 18 years;
  • - WHO performance status 0, 1 or 2;
  • - Written informed consent;
  • - Biopsy-proven newly diagnosed PCa;
  • - International Society of Urological Pathology (ISUP) grade group (GG) >= 3
  • and/or PSA >= 20 ng/ml and/or >=cT3a.
  • If all of the criteria above are met, a subject must also meet all of the
  • following subgroup specific criteria:
  • Group 1 (n=15):
  • - PSMA PET/CT with PSMA-avid primary tumor with PSMA-avid loco-regional and/or
  • distant metastases.
  • Group 2 (n=15):
  • - PSMA PET/CT with PSMA-avid primary tumor with no PSMA-avid loco-regional or
  • distant metastases;
  • - Increased risk of nodal metastases according to the Briganti 2019 nomogram
  • (Briganti >=40%)
  • - Scheduled for (laparoscopic) prostatectomy including ePLND.

排除标准

  • - Known second malignant disease that may complicate image interpretation.
  • - Inability to cooperate with the scan process: inability to lie relatively
  • still and in supine for 30-60 minutes or patient body habitus above scanner
  • dimensions.

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验

The diagnostic value of FAPI PET/CT in staging of... | 临床试验